ENTX

Financial and Business Updates: Entera Bio Ltd. reported progress in its oral peptide therapies, particularly EB613 for osteoporosis, with plans for a Phase 1 study and significant funding secured through partnerships. The company also appointed new executives to strengthen its team.

Osteoporosis Treatment Focus: Entera aims to address the urgent need for effective osteoporosis treatments, highlighting the potential of EB613 as an oral anabolic tablet that could improve bone health in postmenopausal women, while advocating for regulatory reforms to facilitate drug approvals.

EB613 Presentation at WCO-IOF-ESCEO Congress: Entera Bio Ltd. presented positive results from a Phase 2 study of EB613, an oral anabolic treatment for postmenopausal osteoporosis, showing significant improvements in bone mineral density and potential rapid effects on bone strengthening.

Future Development Plans: The company plans to initiate a Phase 3 trial for EB613, aiming to address the treatment gap for high-risk osteoporosis patients who currently lack effective non-injectable therapies.

Company Achievements: Entera Bio Ltd. reported significant advancements in 2024, including the development of oral peptide therapies for osteoporosis and obesity, with plans to initiate a Phase 3 study for their lead candidate EB613, an oral PTH(1-34) treatment for women with osteoporosis.

Financial Overview: The company ended 2024 with $8.7 million in cash, which increased to $21 million by March 2025, allowing them to fund ongoing operations and clinical studies, despite reporting a net loss of $9.5 million for the year.